ClinicalTrials.gg
CompletedNCT01457339Updated Jun 3, 2021Results posted

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

A Phase 1 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Placebo in Schizophrenia, sponsored by Shire. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.

Enrollment
5th of 11
31 · median 20
Started
2011
the only one that year
Phase 1
5 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Schizophrenia by Takeda, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 1, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Schizophrenia by Takeda as a file.
02

Study summary

This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are currently maintained on a stable dose of an antipsychotic medication.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must be diagnosed with schizophrenia, on a stable dose of an antipsychotic and not have any cardiac risk factors

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    SPD489 (Lisdexamfetamine dimesylate)

    Drug: SPD489 (Lisdexamfetamine dimesylate)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.

    Also known as: Vyvanse, LDX

  • DrugPlacebo

    Placebo Capsule(s) for oral use taken once daily for 30 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Systolic Blood Pressure at Day 5: 50 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  2. Change From Baseline in Systolic Blood Pressure at Day 5: 70 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  3. Change From Baseline in Systolic Blood Pressure at Day 5: 100 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  4. Change From Baseline in Systolic Blood Pressure at Day 5: 150 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  5. Change From Baseline in Systolic Blood Pressure at Day 5: 200 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  6. Change From Baseline in Systolic Blood Pressure at Day 5: 250 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  7. Change From Baseline in Diastolic Blood Pressure at Day 5: 50 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  8. Change From Baseline in Diastolic Blood Pressure at Day 5: 70 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  9. Change From Baseline in Diastolic Blood Pressure at Day 5: 100 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  10. Change From Baseline in Diastolic Blood Pressure at Day 5: 150 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  11. Change From Baseline in Diastolic Blood Pressure at Day 5: 200 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  12. Change From Baseline in Diastolic Blood Pressure at Day 5: 250 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  13. Change From Baseline in Pulse Rate at Day 5: 50 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  14. Change From Baseline in Pulse Rate at Day 5: 70 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  15. Change From Baseline in Pulse Rate at Day 5: 100 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  16. Change From Baseline in Pulse Rate at Day 5: 150 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  17. Change From Baseline in Pulse Rate at Day 5: 200 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

  18. Change From Baseline in Pulse Rate at Day 5: 250 mg

    Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

    Time frame: Baseline and day 5

Secondary outcomes

  1. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 50 mg

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Day 5 (12-hour sampling period post-dose)

  2. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 70 mg

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Day 5 (12-hour sampling period post-dose)

  3. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 100 mg

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Day 5 (12-hour sampling period post-dose)

  4. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 150 mg

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Day 5 (12-hour sampling period post-dose)

  5. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 200 mg

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Day 5 (12-hour sampling period post-dose)

  6. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 250 mg

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Day 5 (12-hour sampling period post-dose)

  7. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 50 mg

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Day 5 (12-hour sampling period post-dose)

  8. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 70 mg

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Day 5 (12-hour sampling period post-dose)

  9. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 100 mg

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Day 5 (12-hour sampling period post-dose)

  10. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 150 mg

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Day 5 (12-hour sampling period post-dose)

  11. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 200 mg

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Day 5 (12-hour sampling period post-dose)

  12. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 250 mg

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Day 5 (12-hour sampling period post-dose)

  13. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 50 mg

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  14. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 70 mg

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  15. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 100 mg

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  16. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 150 mg

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  17. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 200 mg

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  18. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 250 mg

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  19. Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 50 mg

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  20. Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 70 mg

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  21. Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 100 mg

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  22. Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 150 mg

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  23. Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 200 mg

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  24. Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 250 mg

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Baseline and Day 5

  25. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 50 mg

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Baseline and Day 5

  26. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 70 mg

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Baseline and Day 5

  27. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 100 mg

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Baseline and Day 5

  28. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 150 mg

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Baseline and Day 5

  29. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 200 mg

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Baseline and Day 5

  30. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 250 mg

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Baseline and Day 5

  31. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 50 mg

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Baseline and Day 5

  32. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 70 mg

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Baseline and Day 5

  33. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 100 mg

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Baseline and Day 5

  34. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 150 mg

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Baseline and Day 5

  35. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 200 mg

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Baseline and Day 5

  36. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 250 mg

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Baseline and Day 5

  37. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 50 mg

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Baseline and Day 5

  38. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 70 mg

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Baseline and Day 5

  39. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 100 mg

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Baseline and Day 5

  40. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 150 mg

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Baseline and Day 5

  41. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 200 mg

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Baseline and Day 5

  42. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 250 mg

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Baseline and Day 5

  43. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 50 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  44. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 70 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  45. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 100 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  46. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 150 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  47. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 200 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  48. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 250 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  49. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 50 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  50. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 70 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  51. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 100 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  52. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 150 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  53. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 200 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  54. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 250 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  55. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 50 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  56. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 70 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  57. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 100 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  58. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 150 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  59. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 200 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  60. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 250 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  61. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 50 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  62. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 70 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  63. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 100 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  64. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 150 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  65. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 200 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

  66. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 250 mg

    This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

    Time frame: Baseline and Day 5

07

Results

Posted Jan 21, 2013

Participant flow

Period 1 (50 mg)
Participant flow — Period 1 (50 mg)
MilestonePlaceboSPD489 (Lisdexamfetamine Dimesylate)
Started724
Completed724
Not completed00
Period 2 (70 mg)
Participant flow — Period 2 (70 mg)
MilestonePlaceboSPD489 (Lisdexamfetamine Dimesylate)
Started724
Completed724
Not completed00
Period 3 (100 mg)
Participant flow — Period 3 (100 mg)
MilestonePlaceboSPD489 (Lisdexamfetamine Dimesylate)
Started724
Completed723
Not completed01
Withdrew: Adverse event01
Period 4 (150 mg)
Participant flow — Period 4 (150 mg)
MilestonePlaceboSPD489 (Lisdexamfetamine Dimesylate)
Started723
Completed723
Not completed00
Period 5 (200 mg)
Participant flow — Period 5 (200 mg)
MilestonePlaceboSPD489 (Lisdexamfetamine Dimesylate)
Started723
Completed722
Not completed01
Withdrew: Met stopping criteria for panss score01
Period 6 (250 mg)
Participant flow — Period 6 (250 mg)
MilestonePlaceboSPD489 (Lisdexamfetamine Dimesylate)
Started722
Completed621
Not completed11
Withdrew: Family emergency10
Withdrew: Personal appointment01

Outcome measures

PrimaryChange From Baseline in Systolic Blood Pressure at Day 5: 50 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at Day 5: 50 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Systolic Blood Pressure at Day 5: 50 mg-0.14 ± 9.5438.94 ± 11.510
PrimaryChange From Baseline in Systolic Blood Pressure at Day 5: 70 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at Day 5: 70 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Systolic Blood Pressure at Day 5: 70 mg1.43 ± 12.5933.82 ± 9.258
PrimaryChange From Baseline in Systolic Blood Pressure at Day 5: 100 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at Day 5: 100 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Systolic Blood Pressure at Day 5: 100 mg0.43 ± 6.4484.96 ± 9.208
SecondaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 50 mg

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng*hr/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 50 mg
ng*hr/mlSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 50 mg25.6 ± 12.9
SecondaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 70 mg

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng*hr/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 70 mg
ng*hr/mlSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 70 mg43.7 ± 27.5
SecondaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 100 mg

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng*hr/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 100 mg
ng*hr/mlSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 100 mg80.5 ± 37.2
SecondaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 150 mg

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng*hr/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 150 mg
ng*hr/mlSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 150 mg144.9 ± 43.7
SecondaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 200 mg

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng*hr/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 200 mg
ng*hr/mlSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 200 mg230.2 ± 81.1
SecondaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 250 mg

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng*hr/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 250 mg
ng*hr/mlSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate on Day 5: 250 mg301.5 ± 105.9
SecondaryMaximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 50 mg

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 50 mg
ng/mlSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 50 mg21.93 ± 9.96
SecondaryMaximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 70 mg

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 70 mg
ng/mlSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 70 mg35.02 ± 21.35
PrimaryChange From Baseline in Systolic Blood Pressure at Day 5: 150 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at Day 5: 150 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Systolic Blood Pressure at Day 5: 150 mg-2.81 ± 7.3586.43 ± 13.519
PrimaryChange From Baseline in Systolic Blood Pressure at Day 5: 200 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at Day 5: 200 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Systolic Blood Pressure at Day 5: 200 mg-2.38 ± 11.5465.28 ± 11.761
PrimaryChange From Baseline in Systolic Blood Pressure at Day 5: 250 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure at Day 5: 250 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Systolic Blood Pressure at Day 5: 250 mg-0.28 ± 13.4427.36 ± 15.569
PrimaryChange From Baseline in Diastolic Blood Pressure at Day 5: 50 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Day 5: 50 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Diastolic Blood Pressure at Day 5: 50 mg2.86 ± 11.5475.22 ± 8.364
PrimaryChange From Baseline in Diastolic Blood Pressure at Day 5: 70 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Day 5: 70 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Diastolic Blood Pressure at Day 5: 70 mg2.38 ± 10.5572.14 ± 6.468
PrimaryChange From Baseline in Diastolic Blood Pressure at Day 5: 100 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Day 5: 100 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Diastolic Blood Pressure at Day 5: 100 mg2.14 ± 7.7964.55 ± 7.641
PrimaryChange From Baseline in Diastolic Blood Pressure at Day 5: 150 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Day 5: 150 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Diastolic Blood Pressure at Day 5: 150 mg2.67 ± 10.8462.43 ± 10.672
PrimaryChange From Baseline in Diastolic Blood Pressure at Day 5: 200 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Day 5: 200 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Diastolic Blood Pressure at Day 5: 200 mg2.76 ± 14.4423.77 ± 8.041
PrimaryChange From Baseline in Diastolic Blood Pressure at Day 5: 250 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Day 5: 250 mg
mmHgPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Diastolic Blood Pressure at Day 5: 250 mg3.67 ± 8.6183.79 ± 10.106
PrimaryChange From Baseline in Pulse Rate at Day 5: 50 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 5: 50 mg
beats/minPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Pulse Rate at Day 5: 50 mg2.62 ± 9.5343.78 ± 11.116
PrimaryChange From Baseline in Pulse Rate at Day 5: 70 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 5: 70 mg
beats/minPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Pulse Rate at Day 5: 70 mg-0.95 ± 9.8215.07 ± 9.500
PrimaryChange From Baseline in Pulse Rate at Day 5: 100 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 5: 100 mg
beats/minPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Pulse Rate at Day 5: 100 mg0.19 ± 10.3065.72 ± 12.578
PrimaryChange From Baseline in Pulse Rate at Day 5: 150 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 5: 150 mg
beats/minPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Pulse Rate at Day 5: 150 mg-1.05 ± 8.1256.41 ± 13.782
PrimaryChange From Baseline in Pulse Rate at Day 5: 200 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 5: 200 mg
beats/minPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Pulse Rate at Day 5: 200 mg2.38 ± 10.0588.88 ± 12.206
PrimaryChange From Baseline in Pulse Rate at Day 5: 250 mg

Blood pressure and pulse measurements were taken using an automated blood pressure monitoring device (ideally using the same device, the same arm and in the same position throughout the study). Measurements of vital signs were performed in triplicate (3 measurements) after the subject had been in a sitting position for at least 5 minutes. Each of the 3 triplicate readings were performed in succession, at least 1-2 minutes apart, with the cuff fully deflated between measurements. It was expected that the triplicate measurements be obtained within a 5-6 minute period.

Time frame:
Baseline and day 5
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 5: 250 mg
beats/minPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Pulse Rate at Day 5: 250 mg2.06 ± 9.76012.39 ± 12.666
SecondaryMaximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 100 mg

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 100 mg
ng/mlSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 100 mg50.6 ± 18.9
SecondaryMaximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 150 mg

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 150 mg
ng/mlSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 150 mg90.34 ± 30.45
SecondaryMaximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 200 mg

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 200 mg
ng/mlSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 200 mg133.3 ± 63.17
SecondaryMaximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 250 mg

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Day 5 (12-hour sampling period post-dose)
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 250 mg
ng/mlSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate on Day 5: 250 mg181.53 ± 72.82
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 50 mg

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 50 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 50 mg0.6 ± 2.22-1.9 ± 1.10
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 70 mg

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 70 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 70 mg-2.1 ± 1.81-2.9 ± 1.50
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 100 mg

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 100 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 100 mg-3.6 ± 1.43-3.9 ± 1.68
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 150 mg

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 150 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 150 mg-2.1 ± 1.40-4.7 ± 1.44
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 200 mg

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 200 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 200 mg-2.3 ± 2.01-4.6 ± 1.81
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 250 mg

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 250 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 5: 250 mg-2.3 ± 2.03-2.4 ± 2.01
SecondaryChange From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 50 mg

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 50 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 50 mg-1.4 ± 1.54-1.7 ± 1.09
SecondaryChange From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 70 mg

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 70 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 70 mg-3.0 ± 2.85-3.1 ± 1.15
SecondaryChange From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 100 mg

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 100 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 100 mg-7.0 ± 3.07-2.6 ± 1.27
SecondaryChange From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 150 mg

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 150 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 150 mg-4.0 ± 3.24-3.0 ± 1.17
SecondaryChange From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 200 mg

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 200 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 200 mg1.3 ± 3.75-2.6 ± 1.11
SecondaryChange From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 250 mg

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 250 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Day 5: 250 mg-4.2 ± 2.15-3.3 ± 1.47
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 50 mg

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 50 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 50 mg0.0 ± 0.38-0.3 ± 0.35
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 70 mg

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 70 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 70 mg-0.4 ± 0.30-0.7 ± 0.28
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 100 mg

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 100 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 100 mg-0.4 ± 0.30-0.9 ± 0.34
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 150 mg

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 150 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 150 mg-0.7 ± 0.47-1.0 ± 0.35
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 200 mg

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 200 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 200 mg-0.4 ± 0.30-0.6 ± 0.28
SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 250 mg

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 250 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Day 5: 250 mg-0.2 ± 0.40-0.3 ± 0.48
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 50 mg

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 50 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 50 mg-0.4 ± 0.300.0 ± 0.18
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 70 mg

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 70 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 70 mg-0.6 ± 0.43-0.1 ± 0.18
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 100 mg

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 100 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 100 mg-0.4 ± 0.480.0 ± 0.21
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 150 mg

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 150 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 150 mg-0.3 ± 0.290.1 ± 0.19
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 200 mg

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 200 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 200 mg0.0 ± 0.520.0 ± 0.20
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 250 mg

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 250 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Day 5: 250 mg0.2 ± 0.310.0 ± 0.21
SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 50 mg

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 50 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 50 mg0.0 ± 0.000.0 ± 0.00
SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 70 mg

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 70 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 70 mg0.0 ± 0.000.0 ± 0.00
SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 100 mg

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 100 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 100 mg0.0 ± 0.000.0 ± 0.00
SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 150 mg

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 150 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 150 mg0.0 ± 0.000.0 ± 0.00
SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 200 mg

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 200 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 200 mg0.0 ± 0.000.2 ± 0.11
SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 250 mg

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Baseline and Day 5
Reported as:
Mean · units on a scale
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 250 mg
units on a scalePlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at Day 5: 250 mg0.0 ± 0.000.0 ± 0.05
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 50 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 50 mg
Number of ErrorsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 50 mg-0.9 ± 8.02-8.2 ± 5.79
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 70 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 70 mg
Number of ErrorsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 70 mg8.7 ± 10.77-7.3 ± 6.45
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 100 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 100 mg
Number of ErrorsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 100 mg0.9 ± 9.55-15.7 ± 6.57
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 150 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 150 mg
Number of ErrorsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 150 mg21.1 ± 28.75-11.3 ± 6.26
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 200 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 200 mg
Number of ErrorsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 200 mg-10.3 ± 6.30-16.5 ± 6.65
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 250 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 250 mg
Number of ErrorsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Groton Maze Learning Test, 250 mg-5.0 ± 8.74-13.2 ± 5.25
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 50 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 50 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 50 mg0.0 ± 0.0389-0.034 ± 0.0223
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 70 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 70 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 70 mg0.017 ± 0.0411-0.015 ± 0.0195
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 100 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 100 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 100 mg0.014 ± 0.0492-0.047 ± 0.0246
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 150 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 150 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 150 mg0.037 ± 0.0373-0.039 ± 0.0180
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 200 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 200 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 200 mg-0.025 ± 0.0395-0.049 ± 0.0178
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 250 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 250 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Detection Task, 250 mg-0.034 ± 0.0581-0.048 ± 0.0147
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 50 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 50 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 50 mg0.028 ± 0.03040.001 ± 0.0141
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 70 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 70 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 70 mg0.015 ± 0.02730.006 ± 0.0113
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 100 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 100 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 100 mg0.011 ± 0.03480.001 ± 0.0171
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 150 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 150 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 150 mg0.036 ± 0.0419-0.010 ± 0.0172
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 200 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 200 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 200 mg0.044 ± 0.0397-0.014 ± 0.0157
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 250 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Log10 milliseconds
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 250 mg
Log10 millisecondsPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: Identification Task, 250 mg0.005 ± 0.0531-0.007 ± 0.0144
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 50 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Arcsine proportion correct
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 50 mg
Arcsine proportion correctPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 50 mg0.025 ± 0.02340.005 ± 0.0179
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 70 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Arcsine proportion correct
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 70 mg
Arcsine proportion correctPlaceboSPD489 (Lisdexamfetamine Dimesylate)(70 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 70 mg0.015 ± 0.03220.021 ± 0.0189
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 100 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Arcsine proportion correct
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 100 mg
Arcsine proportion correctPlaceboSPD489 (Lisdexamfetamine Dimesylate)(100 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 100 mg0.012 ± 0.03730.012 ± 0.0197
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 150 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Arcsine proportion correct
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 150 mg
Arcsine proportion correctPlaceboSPD489 (Lisdexamfetamine Dimesylate)(150 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 150 mg0.026 ± 0.04150.042 ± 0.0222
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 200 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Arcsine proportion correct
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 200 mg
Arcsine proportion correctPlaceboSPD489 (Lisdexamfetamine Dimesylate)(200 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 200 mg-0.020 ± 0.03940.046 ± 0.0219
SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 250 mg

This battery is a series of 4 computerized cognition tests (Groton Maze Learning Test, Detection Task, Identification Task, and One Card Learning Task) designed to measure reaction time, visual learning and reasoning, and problem solving. The entire battery takes approximately 12 minutes to complete. CogState scores are measured on a linear scale (no maximum score). The Groton Maze Learning Test measures total number of errors made in problem solving (lower score = better performance). The Detection Task is measured by speed of performance (lower score = better performance). The Identification Task is measured by speed of performance (lower score = better performance). One Card Learning Task measures the accuracy of performance (higher score = better performance).

Time frame:
Baseline and Day 5
Reported as:
Mean · Arcsine proportion correct
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 250 mg
Arcsine proportion correctPlaceboSPD489 (Lisdexamfetamine Dimesylate)(250 mg)
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Day 5: One Card Learning Task, 250 mg0.018 ± 0.04320.022 ± 0.0250

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/7 (0%)4/7 (57.1%)
SPD489 (Lisdexamfetamine Dimesylate)(50 mg)—0/24 (0%)15/24 (62.5%)
SPD489 (Lisdexamfetamine Dimesylate)(70 mg)—0/24 (0%)7/24 (29.2%)
SPD489 (Lisdexamfetamine Dimesylate)(100 mg)—0/24 (0%)8/24 (33.3%)
SPD489 (Lisdexamfetamine Dimesylate)(150 mg)—0/23 (0%)12/23 (52.2%)
SPD489 (Lisdexamfetamine Dimesylate)(200 mg)—0/23 (0%)10/23 (43.5%)
SPD489 (Lisdexamfetamine Dimesylate)(250 mg)—0/22 (0%)12/22 (54.5%)
SPD489 (Lisdexamfetamine Dimesylate)(All Doses)—0/24 (0%)23/24 (95.8%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboSPD489 (Lisdexamfetamine Dimesylate)(50 mg)SPD489 (Lisdexamfetamine Dimesylate)(70 mg)SPD489 (Lisdexamfetamine Dimesylate)(100 mg)SPD489 (Lisdexamfetamine Dimesylate)(150 mg)SPD489 (Lisdexamfetamine Dimesylate)(200 mg)SPD489 (Lisdexamfetamine Dimesylate)(250 mg)SPD489 (Lisdexamfetamine Dimesylate)(All Doses)
TachycardiaCardiac disorders2/73/241/241/242/230/231/226/24
ConstipationGastrointestinal disorders0/70/242/240/240/233/230/225/24
InsomniaPsychiatric disorders0/73/241/241/242/230/231/225/24
TremorNervous system disorders1/71/241/241/242/231/231/225/24
HeadacheNervous system disorders1/71/240/241/244/231/234/224/24
NauseaGastrointestinal disorders1/70/240/240/243/232/232/224/24
Decreased appetiteMetabolism and nutrition disorders0/74/240/240/240/230/230/224/24
AnxietyPsychiatric disorders0/72/241/240/240/230/232/224/24
Increased AppetiteMetabolism and nutrition disorders1/71/240/240/240/230/231/222/24
VomitingGastrointestinal disorders1/70/240/240/240/230/231/221/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboSPD489 (Lisdexamfetamine Dimesylate)(All Doses)Total
<=18 years000
Between 18 and 65 years72431
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboSPD489 (Lisdexamfetamine Dimesylate)(All Doses)Total
Mean49.6 ± 4.9346.4 ± 7.8647.1 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSPD489 (Lisdexamfetamine Dimesylate)(All Doses)Total
Female156
Male61925
Region of Enrollment
Region of Enrollment(Participants)PlaceboSPD489 (Lisdexamfetamine Dimesylate)(All Doses)Total
United States72431
08

Study locations

2 sites
  • California Clinical Trials
    Glendale, California 91206, United States
  • Collaborative Neuroscience Network, Inc
    Long Beach, California 90806, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Jan 2012, 2 months.

Results were first posted in Jan 2013, 1 year after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2011
First posted
Oct 21, 2011
StartActual
Oct 21, 2011
Primary completionActual
Jan 20, 2012
CompletionActual
Jan 20, 2012
Results first posted
Jan 21, 2013
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01457339
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 21, 2011
Start date
Oct 21, 2011
Primary completion
Jan 20, 2012
Completion
Jan 20, 2012
Results posted
Jan 21, 2013
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion